Highlights Zealand Pharma A/S

Equities

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2026-06-04 am EDT			5-day change	1st Jan Change
326.30 ^DKK	+9.02%		+0.43%	-30.04%

Jun. 05	Zealand touts promising tolerability data for obesity drug in mid-stage study	RE
Jun. 05	Zealand Pharma A/S Presents Additional Data From Phase 2 ZUPREME-1 Trial Evaluating Petrelintide At The American Diabetes Association 2026 Scientific Sessions	CI

Highlights

Jun. 05	Zealand Pharma A/S Presents Additional Data From Phase 2 ZUPREME-1 Trial Evaluating Petrelintide At The American Diabetes Association 2026 Scientific Sessions	CI
May. 14	Zealand Pharma A/S commences an Equity Buyback Plan, under the authorization approved on March 26, 2026.	CI
May. 07	Zealand Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 07	Zealand Pharma Kicks Off DKK1.3 Billion Share Buyback	MT
May. 07	Zealand Pharma Q1 EBIT loss DKK 539 mln	RE
May. 07	Zealand unveils buyback, Roche payments; shares rise	RE
May. 07	Zealand Pharma initiates $200 mln share buy-back program	RE
Apr. 28	Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial	RE
Apr. 28	Boehringer: Survodutide, licensed from Zealand Pharma, met primary trial goals on weight loss and secondary goal on waist circumference	RE
Apr. 28	Zealand Pharma Announces Boehringer Ingelheim's Survodutide Achieves Significant Weight Loss and Metabolic Improvement in Phase 3 Trial	CI
Mar. 24	Danish Biotech Group Zealand Pharma to Open New Research Hub in US	MT
Mar. 24	Zealand Pharma Establishes U.S. Research Hub in Cambridge Massachusetts	CI
Mar. 06	Health Care Down, but not by Much, Amid Defensive Bias - Health Care Roundup	DJ
Mar. 05	Zealand Pharma Announces Positive Phase 2 Results for Petrelintide	CI
Feb. 19	Zealand Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Feb. 19	Zealand Pharma FY revenue up at DKK 9,215 million	RE
Feb. 18	Zealand Pharma A/S Announces Positive Phase 1a Topline Results with Kv1.3 Channel Backer ZP9830	CI
Jan. 09	Zealand Pharma to Boost Drug Discovery via Denmark Supercomputer	MT
Dec. 11	OTR Therapeutics and Zealand Pharma A/S Enter Multi- Program Strategic Collaboration and License Agreement to Develop Novel Therapies for Metabolic Diseases	CI
Dec. 11	Zealand Pharma outlines Metabolic Frontier 2030 strategy	RE
Nov. 13	Zealand Pharma pauses development of early-stage obesity drug candidate	RE
Nov. 13	Zealand Pharma Q3 operating loss DKK 461.3 million	RE
Nov. 13	Zealand Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-14	Zealand Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-14	Zealand Pharma keeps FY guidance unchanged	RE